Clinical Trial Update: Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Entresto (sacubitril/valsartan) to olmesartan in elderly patients with essential hypertension to assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Entresto (sacubitril/valsartan)
• Olmesartan (olmesartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2015-08-18